Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Patients with Type 2 Diabetes with not very well controlled high blood pressure taking medicine called Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and Medication to reduce high Blood Preassure in addition. The Phase 3 Trial is carried out at several sites and neither patients nor doctors know which study treatment (medication in different strength or dummy treatment) they are assigned to
• To compare the change from baseline in seated systolic blood pressure after 12 weeks of double-blind treatment with dapagliflozin 10 mg treatment group and the placebo treatment group. • To compa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND EXTRAPOLATED EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT
To assess the safety and extrapolated efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
An Open-Label, Two-Stage, Fixed-Dose, Multicenter Phase II Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease
To measure best objective response rate up to Day 106 in patients with relapsed or refractory Hodgkin's disease administered MDX-060.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension
The primary objective of this study is to compare the proportion of subjects whose seated diastolic blood pressure (SeDBP) is controlled (SeDBP < 90mmHg) at Week 5 when initiating irbesartan 150mg/HCT...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Functioning of a Treatment with Aripiprazole in a Broad Range of Schizophrenic Patients
To evaluate the effectiveness of a 12-week treatment with aripiprazole in a broad range of schizophrenic patients. The overall effectiveness will be evaluated by the CGI-I at Week 12.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Irbesartan versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Hypertensive Albuminuria in Subjects at Elevated Cardiovascular Risk
To compare the change in albumin excretion rate (AER) measured in overnight urine collections from baseline to week 20 between groups assigned to ramipril and irbesartan or to ramipril and placebo in ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin Alone or on Insulin in Combination with Metformin Revised Protocol 02 incorporating Protocol Amendment 02 (v1.0, 15-Dec-2008) and Protocol Amendment 03 (v1.0, 04-Nov-2009) + Pharmacogenetics Blood Sample Protocol Amendment 1 (v1.0, 13-Aug-2008)
To compare the effects of saxagliptin versus placebo as add-on therapy to insulin (or to insulin combined with metformin) in improving glycemic control (A1C) at 24 weeks (or rescue).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, version 2.0 dated 13-Feb-05 Revised Protocol 03, version v8.0, incorporating Protocol Amendments 03, 04 and 05
To compare changes in trunk-to-limb fat ratio at week 48 by dual energy x-ray absorptiometry (DEXA) in HIV-1 infected subjects with lipohypertrophy, after switching to an ATV/RTV containing regimen ve...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Phase IIB Dose Ranging Study of BMS-945429 in subjects with moderate to severe Crohn’s Disease
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn’s disease and who have had an insufficient response to conv...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Dose Frequency Optimization Study with Nivolumab Every 2 Weeks vsNivolumab Every 4 Weeks in advanced NSCLC patients Who Received 4 Months of Nivolumab Every 2 Weeks Estudio de optimización de la dosis de frecuencia con Nivolumab cada 2 semanas vs Nivolumab cada 4 semanas en pacientes con CPNM avanzado que recibieron 4 Meses de Nivolumab cada 2 semanas
The coprimary objectives are to compare Progression Free Survival rate at 6 months after randomization and PFS rate at 1 year after randomization, as measured by investigator-assessed response using ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
5
6
7
8
9
10
11
12
13
14
Suivant